1-methyl-3-[(5-methyl-3-oxo-2H-[1,2,4]triazolo[4,3-c]pyrimidin-7-yl)amino]pyrrolidine-2,5-dione
C11H12N6O3 — CID 66281422
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-methyl-3-[(5-methyl-3-oxo-2H-[1,2,4]triazolo[4,3-c]pyrimidin-7-yl)amino]pyrrolidine-2,5-dione
1-methyl-3-[(5-methyl-3-oxo-2H-[1,2,4]triazolo[4,3-c]pyrimidin-7-yl)amino]pyrrolidine-2,5-dione (PubChem CID 66281422) has the molecular formula C11H12N6O3 and a molecular weight of 276.26 g/mol. Its IUPAC name is 1-methyl-3-[(5-methyl-3-oxo-2H-[1,2,4]triazolo[4,3-c]pyrimidin-7-yl)amino]pyrrolidine-2,5-dione.
Molecular Properties
| Compound Name | 1-methyl-3-[(5-methyl-3-oxo-2H-[1,2,4]triazolo[4,3-c]pyrimidin-7-yl)amino]pyrrolidine-2,5-dione |
|---|---|
| PubChem CID | 66281422 |
| Molecular Formula | C11H12N6O3 |
| Molecular Weight | 276.26 g/mol |
| Exact Mass | 276.10 |
| IUPAC Name | 1-methyl-3-[(5-methyl-3-oxo-2H-[1,2,4]triazolo[4,3-c]pyrimidin-7-yl)amino]pyrrolidine-2,5-dione |
| SMILES | Cc1nc(NC2CC(=O)N(C)C2=O)cc2n[nH]c(=O)n12 |
| InChI | InChI=1S/C11H12N6O3/c1-5-12-7(4-8-14-15-11(20)17(5)8)13-6-3-9(18)16(2)10(6)19/h4,6,13H,3H2,1-2H3,(H,15,20) |
| InChIKey | QPQGEUCZNJVKRU-UHFFFAOYSA-N |
| XLogP | -1.10 |
| TPSA | 112.46 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 2 |
| Heavy Atoms | 20 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 276.26 |
| LogP ≤ 5 | -1.10 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 7 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'phthalimide', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 66281422 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.